NANTBIOSCIENCE INC has a total of 51 patent applications. It increased the IP activity by 50.0%. Its first patent ever was published in 2010. It filed its patents most often in Australia, United States and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals and organic fine chemistry are FARMAK INTERNAT HOLDING GMBH, PHENEX PHARMACEUTICALS AG and CHEMBRIDGE CORP.
# | Country | Total Patents | |
---|---|---|---|
#1 | Australia | 9 | |
#2 | United States | 9 | |
#3 | EPO (European Patent Office) | 5 | |
#4 | WIPO (World Intellectual Property Organization) | 5 | |
#5 | Canada | 4 | |
#6 | China | 4 | |
#7 | Republic of Korea | 4 | |
#8 | Brazil | 3 | |
#9 | Israel | 3 | |
#10 | Hong Kong | 2 | |
#11 | Russian Federation | 2 | |
#12 | Japan | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Heterocyclic compounds | |
#3 | Medical preparations | |
#4 | Special acyclic compounds |
# | Name | Total Patents |
---|---|---|
#1 | Tao Chunlin | 41 |
#2 | Ho David | 27 |
#3 | Weingarten Paul | 27 |
#4 | Polat Tulay | 25 |
#5 | Wang Qinwei | 25 |
#6 | Nallan Laxman | 24 |
#7 | Arp Forrest | 22 |
#8 | Soon-Shiong Patrick | 11 |
#9 | Chunlin Tao | 6 |
#10 | Rabizadeh Shahrooz | 6 |
Publication | Filing date | Title |
---|---|---|
WO2017004274A2 | Compositions and methods of rit1 inhibition | |
RU2701188C2 | Pyrimidine derivatives as kinase inhibitors and therapeutic applications thereof | |
AU2014227487A1 | Triazine derivatives and their therapeutical applications | |
AU2014233069A1 | Substituted indol-5-ol derivatives and their therapeutic applications | |
AU2014200125A1 | Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling | |
AU2013337370A1 | Cyclic sulfonamide containing derivatives as inhibitors of hedgehog signaling pathway | |
AU2010259009A1 | Triazine derivatives and their therapeutical applications |